Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417789 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL13483931 | 0.97 | TSHR (0.40) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL11760325 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL11763958 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL18489485 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL24183668 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL24864672 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL11760319 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL11760910 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL2887421 | 0.95 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394996-B2 | Method for producing aldehyde functional compounds | EVONIK DEGUSSA GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20120022276-A1 | METHOD FOR PRODUCING ALDEHYDE FUNCTIONAL COMPOUNDS | EVONIK DEGUSSA GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2382178-A1 | METHOD FOR PRODUCING ALDEHYDE FUNCTIONAL COMPOUNDS | Evonik Degussa GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010084053-A1 | METHOD FOR PRODUCING ALDEHYDE FUNCTIONAL COMPOUNDS | EVONIK DEGUSSA GMBH (DE) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022276-A1 | METHOD FOR PRODUCING ALDEHYDE FUNCTIONAL COMPOUNDS | FASN, ALDH2, ALOX12 | TSHR 4779/4885THRB 4603/4885FAAH 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.